James C Hamilton, the Chief Medical Officer of $ARWR, sold 15,000 shares of the company on 09-02-2025 for an estimated $375,000. We received data on the trade from a recent SEC filing. This was a sale of approximately 5.7% of their shares of this class of stock. Following this trade, they now own 247,122 shares of this class of $ARWR stock.
$ARWR Insider Trading Activity
$ARWR insiders have traded $ARWR stock on the open market 9 times in the past 6 months. Of those trades, 0 have been purchases and 9 have been sales.
Here’s a breakdown of recent trading of $ARWR stock by insiders over the last 6 months:
- CHRISTOPHER RICHARD ANZALONE (Chief Executive Officer) has made 0 purchases and 6 sales selling 192,547 shares for an estimated $2,308,311.
- JAMES C HAMILTON (Chief Medical Officer) has made 0 purchases and 3 sales selling 25,000 shares for an estimated $575,000.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$ARWR Hedge Fund Activity
We have seen 149 institutional investors add shares of $ARWR stock to their portfolio, and 156 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- VANGUARD GROUP INC added 2,322,510 shares (+17.6%) to their portfolio in Q2 2025, for an estimated $36,695,658
- UBS AM, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS LLC removed 2,100,745 shares (-43.9%) from their portfolio in Q2 2025, for an estimated $33,191,771
- MARSHALL WACE, LLP added 2,096,238 shares (+3507.8%) to their portfolio in Q2 2025, for an estimated $33,120,560
- FMR LLC added 1,855,228 shares (+56.0%) to their portfolio in Q2 2025, for an estimated $29,312,602
- T. ROWE PRICE INVESTMENT MANAGEMENT, INC. removed 1,706,639 shares (-67.5%) from their portfolio in Q2 2025, for an estimated $26,964,896
- BAKER BROS. ADVISORS LP added 939,174 shares (+inf%) to their portfolio in Q2 2025, for an estimated $14,838,949
- CITADEL ADVISORS LLC removed 924,706 shares (-93.7%) from their portfolio in Q2 2025, for an estimated $14,610,354
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$ARWR Analyst Ratings
Wall Street analysts have issued reports on $ARWR in the last several months. We have seen 3 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- HC Wainwright & Co. issued a "Buy" rating on 09/02/2025
- Chardan Capital issued a "Buy" rating on 08/11/2025
- RBC Capital issued a "Outperform" rating on 08/08/2025
To track analyst ratings and price targets for $ARWR, check out Quiver Quantitative's $ARWR forecast page.
$ARWR Price Targets
Multiple analysts have issued price targets for $ARWR recently. We have seen 5 analysts offer price targets for $ARWR in the last 6 months, with a median target of $60.0.
Here are some recent targets:
- Patrick R. Trucchio from HC Wainwright & Co. set a target price of $80.0 on 09/02/2025
- Keay Nakae from Chardan Capital set a target price of $60.0 on 08/11/2025
- Luca Issi from RBC Capital set a target price of $38.0 on 08/08/2025
- Shawn Egan from Citigroup set a target price of $17.0 on 05/13/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information.
